High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
Juan José Lahuerta, Jesús San-Miguel, Ana Jiménez-Ubieto, Rafael Alonso, Bruno Paiva, Noemí Puig, M Teresa Cedena, Norma Carmen Gutierrez, María José Calasanz, Manuela Fernández Guijarro, Rafael Ríos Tamayo, Albert Oriol Rocafiguera, María Jesús Blanchard, Estrella Carrillo Cruz, Rafael Martínez-Martínez, Joan Bargay, Ana Sureda Balari, Javier de la Rubia, Miguel Teodoro Hernández García, Valentín Cabañas, Felipe Casado Montero, Luis Palomera Bernal, Yolanda González Montes, Joaquín Martínez-Lopez, Paula Rodriguez-Otero, Isabel Krisnik, José M Arguiñano, María Esther Gonzalez García, Enrique M Ocio, Javier de la Cruz, María Victoria Mateos, Laura Rosiñol, Joan Bladé
Blood 146(15) 1747-1758
摘要
摘要
In retrospective studies, autologous stem cell transplantation (ASCT) conditioning with intravenous busulfan and melphalan (BUMEL) led to longer progression-free survival (PFS) than melphalan alone (MEL200). We compared long-term outcomes of BUMEL vs MEL200 in the context of intensified bortezomib, lenalidomide, and dexamethasone (VRD) induction and consolidation therapies. GEM12 was a phase 3 trial for patients with newly diagnosed multiple myeloma (NDMM) eligible for ASCT including 6 reinforced VRD cycles followed by ASCT conditioned with BUMEL or MEL200 and 2 VRD consolidation cycles. The primary end point was PFS. Subgroup analyses were based on International Staging System (ISS) stages and high-risk genetic abnormalities. Patients were randomized with an open-label 2 × 2 factorial design and 1:1:1:1 allocation ratio to ensure the balance between the GEM12 and the subsequent phase 3 GEM14 trial. Between 2013 and 2015, 458 patients were randomized (BUMEL, n = 230; MEL200, n = 228). The 10⁻⁶ MRD-negative rate was 63%, 68% for BUMEL vs 58% for MEL200 (odds ratio, 1.51; P = .035). The median PFS was 89 months for BUMEL and 73.1 for MEL200 (hazard ratio, 0.89 [95% confidence interval, 0.70-1.14]; P = .3). BUMEL showed benefit for patients with ISS stages II or III, t(14;16), and del(1p). For subcohorts ISS stages II or III treated with BUMEL and ISS I treated with MEL200 the median PFS was 96.5 months (95% confidence interval, 76 to not estimable). No safety concerns were observed. After a median follow-up of 8.4 years, GEM2012 demonstrated one of the longest PFS values reported in patients with NDMM, with significant differences favoring BUMEL in advanced ISS stages. The trial was registered at www.ClinicalTrials.gov as #NCT01916252 and at European Union Drug Regulating Authorities Clinical Trials as EudraCT 2012-005683-10.
KM 提取结果
0 个 Figure · 0 个 KM 面板